Shengxiang Ren
0000-0001-8767-9850
4 papers found
Refreshing results…
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation
Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase ( ALK )‐rearranged non‐small cell lung cancer
Larger tumors are associated with inferior progression‐free survival of first‐line EGFR‐tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non‐small cell lung cancer
EGFR‐TKIs plus local therapy demonstrated survival benefit than EGFR‐TKIs alone in EGFR‐mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases
Missing publications? Search for publications with a matching author name.